Skip to main content
Mirube

Sepsis - Quarterly Reports

List of quarterly reports on Sepsis

Sepsis Research Analysis

Sepsis research in 2026-Q3 showed a clear transition from nonspecific syndrome management toward biologically defined, organ-specific, and phenotype-adapted strategies. Molecular diagnostics advanced from prospective paired-specimen ddPCR and direct-from-blood pathogen testing to a large randomized trial, while genomic epidemiology identified actionable reservoirs of neonatal antimicrobial-resistant transmission. Mechanistic research expanded knowledge of microbiota-derived metabolites, macropha

Sepsis Research Analysis

Q2 2026 sepsis research converged on host-directed control of inflammation and injury, rapid resistance diagnostics, and organ-specific metabolic therapy. April inaugurated an inflammasome-focused wave with an LRR-binding NLRP3 inhibitor (LOC14) and dual NLRP3–NCF1 redox targeting, which set the stage for May’s repurposed NLRP3 inhibitor ciclopirox with immediate translational potential. Cross-cutting immunometabolism advanced through discovery that itaconate alkylates AIM2 to trigger macrophage

Sepsis Research Analysis

Q1 2026 sepsis research converged on biology-informed triage, rapid bedside subphenotyping, and host-directed therapeutics. Pragmatic clinical implementation advanced with procalcitonin-guided ED workflows reducing 28-day mortality and a 1-hour IL-6/sTNFR1+bicarbonate panel enabling ARDS subphenotype assignment for precision enrollment. Parsimonious biomarker frameworks (cDIP) operationalized immune dysregulation and identified steroid-responsive patients, while multi-omic risk enrichment (BEYON

Sepsis Research Analysis

Sepsis research during 2025-Q4 shifted decisively from syndrome-level treatment toward dynamic, biologically stratified care. Large human studies established that infection source, age, longitudinal molecular state, and treatment-response signatures are major determinants of heterogeneity. The quarter also produced important methodological advances, including goal-directed multi-omics subgrouping, rapid time-resolved transcriptomics, explainable AI, and integrated single-cell immune mapping. Cli

Sepsis Research Analysis

The third quarter of 2025 marked a clear movement in sepsis research from nonspecific inflammation control toward biologically stratified, mechanism-directed intervention. Across the quarter, studies converged on immunometabolic regulation, pyroptosis and NETosis, endothelial–myeloid communication, gut–brain signaling, and immune-collapse mechanisms as actionable determinants of organ dysfunction and mortality. Diagnostic science also advanced through temporal-graph electronic health-record mode

Sepsis Research Analysis

The second quarter of 2025 marked a transition from syndrome-based sepsis research toward biologically stratified, organ-specific, and pathogen-informed precision medicine. Large-scale proteomic, transcriptomic, metabolomic, and microfluidic studies advanced the ability to identify injured organs, predict deterioration, infer pathogen class, and define immune-treatment phenotypes. Mechanistic studies expanded the therapeutic landscape from nonspecific immunosuppression toward targeted regulation

Sepsis Research Analysis

Sepsis research in 2025-Q1 moved decisively toward mechanism-based and phenotype-specific science rather than nonspecific immunomodulation. Studies identified interconnected host–microbiome–pathogen mechanisms, including AhR–enterobactin signaling, TLR4-driven luminal redox disruption, tissue macrophage barriers, and extracellular-vesicle-mediated endothelial ferroptosis. Translational work also expanded the therapeutic pipeline through pathogen-derived carbon dots, fluoxetine-mediated immunomet